Asia · Regional markets · Vietnam Investment Review

BioVersys initiates Phase 2b trial for anti infective drug BV100

Published by Vietnam Investment Review · Vietnam 17 h ago

Biotechnology company BioVersys enrolled the first patient in its Phase 2b trial evaluating anti-infective drug candidate BV100 for treating drug-resistant bacterial pneumonia.

Read the full article on Vietnam Investment Review Sign in to save

MarketNews shows the headline and summary published by the outlet. The full article is on the publisher's website. (vir.com.vn)

Also worth reading

CNBC-TV18

Sensex, Nifty extend gains for 2nd day: IT stocks lead rally, broader market underperforms

The Straits Times Business

Foxconn working on a new tie-up with OpenAI, says there is no AI bubble

Tech in Asia

Init 6 invests in Indonesian AI infra startup Netra Runtime

Mint

Stock to buy after Q2 Results 2026: Anand Rathi sees 25% upside in this IT stock in 12 months | Target price, rationale

Business Standard

Nifty Pharma index hits record high; Sun, Laurus, Zydus, Sai rally up to 6%

The Business Times